Page last updated: 2024-08-24

mibefradil and Glial Cell Tumors

mibefradil has been researched along with Glial Cell Tumors in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Desai, AS; Desideri, S; Fisher, JD; Grossman, SA; Holdhoff, M; Leal, J; Lesser, GJ; Lieberman, FS; Lodge, MA; Nabors, LB; Read, WL; Schiff, D; Supko, JG; Wahl, RL; Walbert, T; Ye, X	1

Trials

1 trial(s) available for mibefradil and Glial Cell Tumors

Article	Year
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. Neuro-oncology, 2017, 06-01, Volume: 19, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Calcium Channels, T-Type; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Mibefradil; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Young Adult	2017

Article

Year

Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.

Neuro-oncology, 2017, 06-01, Volume: 19, Issue:6

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Calcium Channels, T-Type; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Mibefradil; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Young Adult

2017